31 Participants Needed

Automated Abdominal Binder for Orthostatic Hypotension

EC
BK
Luis Okamoto, MD | Vanderbilt Autonomic ...
Overseen ByLuis E Okamoto, MD
Age: 18+
Sex: Any
Trial Phase: Phase 1 & 2
Sponsor: Vanderbilt University Medical Center
No Placebo GroupAll trial participants will receive the active study treatment (no placebo)
Approved in 1 JurisdictionThis treatment is already approved in other countries

Trial Summary

What is the purpose of this trial?

This trial is testing a special belt that inflates to help people with low blood pressure when they stand up. It targets patients who have a condition that makes it hard for them to keep their blood pressure stable. The belt works by squeezing the abdomen to help keep blood flowing properly when standing.

Will I have to stop taking my current medications?

The trial does not specify if you need to stop taking your current medications, but it does exclude those using anticoagulants (blood thinners).

What data supports the effectiveness of the Automated Abdominal Binder treatment for orthostatic hypotension?

Research shows that an automated inflatable abdominal binder can improve orthostatic tolerance (ability to stand without symptoms) similarly to midodrine, a common medication for orthostatic hypotension. The binder reduces orthostatic symptoms by providing sustained pressure, which helps manage blood flow when standing.12345

Is the Automated Abdominal Binder safe for use in humans?

The Automated Abdominal Binder has been shown to affect blood flow and pressure in the body, which can be beneficial for certain conditions like orthostatic hypotension. However, it should be used with caution, especially when lying down for long periods, as it may increase the risk of blood clots in the legs.12345

How does the Automated Abdominal Binder treatment differ from other treatments for orthostatic hypotension?

The Automated Abdominal Binder is unique because it provides targeted, adjustable pressure to the abdomen to prevent blood from pooling in the splanchnic veins (veins in the abdomen) when standing, unlike traditional medications that do not specifically address this issue. It is activated only when standing, offering a non-drug alternative that directly addresses the cause of orthostatic hypotension.12356

Research Team

IB

Italo Biaggioni, MD

Principal Investigator

Professor of Medicine and Pharmacology

LE

Luis E Okamoto, MD

Principal Investigator

Research Assistant Professor

Eligibility Criteria

This trial is for adults aged 40-80 with Multiple System Atrophy or Pure Autonomic Failure, who experience significant drops in blood pressure upon standing and have related symptoms impacting their quality of life. Pregnant individuals, those with certain systemic illnesses, recent surgery patients, and people on anticoagulants cannot participate.

Inclusion Criteria

My blood pressure drops significantly when I stand, due to nerve issues.
I often feel dizzy or faint when standing up, and it affects my daily life.
I am between 40 and 80 years old.
See 7 more

Exclusion Criteria

I have not had major surgery, severe hernias, intense acid reflux, recent bone fractures, or devices that could interfere with abdominal pressure in the last 6 months.
I am bedridden or cannot stand due to severe mobility issues.
I haven't had a heart attack, stroke, or severe chest pain in the last 6 months.
See 4 more

Timeline

Screening

Participants are screened for eligibility to participate in the trial

1-2 weeks
1 visit (in-person)

Baseline Measurements

Participants undergo baseline measurements with placebo pill administration

1 day
1 visit (in-person)

Treatment

Participants receive treatment with 10 mg midodrine t.i.d and automated or sham abdominal binder

3 days
3 visits (in-person, two days apart)

Follow-up

Participants are monitored for safety and effectiveness after treatment

2 weeks

Treatment Details

Interventions

  • Automated Abdominal Binder
  • Midodrine
  • Placebo
  • Sham Binder
Trial Overview The study tests an automated abdominal binder against a sham binder to see if it helps manage low blood pressure when standing due to autonomic failure. Participants may also receive Midodrine (a drug for low blood pressure) or placebo as part of the trial.
Participant Groups
2Treatment groups
Experimental Treatment
Placebo Group
Group I: Automated Abdominal BinderExperimental Treatment3 Interventions
Participants will be studied on three separate study days, two days apart: one day for baseline measurements (placebo pill t.i.d), one day for treatment with 10 mg midodrine t.i.d (standard of care), and one day for treatment with the automated abdominal binder combined with placebo pill t.i.d The automated abdominal binder will be placed during the morning orthostatic trial on the active/sham binder study day. The binder will inflate automatically (\~40 mmHg) every time the participant stands up throughout the study day.
Group II: Sham binderPlacebo Group3 Interventions
Participants will be studied on three separate study days, two days apart: one day for baseline measurements (placebo pill t.i.d), one day for treatment with 10 mg midodrine t.i.d (standard of care), and one day for treatment with the sham binder combined with placebo pill t.i.d. The sham binder will be placed during the morning orthostatic trial on the active/sham binder study day. The sham binder will inflate automatically (\~5 mmHg) every time the participant stands up throughout the study day.

Automated Abdominal Binder is already approved in United States for the following indications:

๐Ÿ‡บ๐Ÿ‡ธ
Approved in United States as Automated Abdominal Binder for:
  • Orthostatic Hypotension

Find a Clinic Near You

Who Is Running the Clinical Trial?

Vanderbilt University Medical Center

Lead Sponsor

Trials
922
Recruited
939,000+

National Heart, Lung, and Blood Institute (NHLBI)

Collaborator

Trials
3,987
Recruited
47,860,000+

Findings from Research

The 'Ball and Binder' device, an innovative and low-cost pneumatic abdominal compression tool, significantly reduced distal aortic blood flow by over 50% in a study of nine healthy volunteers.
This device offers a promising new option for rapidly treating postpartum hemorrhage, especially in cases where standard treatments are ineffective.
Control of Pelvic Blood Flow Using a Novel Pneumatic Abdominal Binder.[2021]
The use of an abdominal binder significantly improved respiratory function in individuals with tetraplegic spinal cord injuries, enhancing vital capacity and forced vital capacity after a 6-week trial.
However, the abdominal binder did not show any significant benefits for speech production, as no improvements were observed in various speech parameters.
Impact of an abdominal binder on speech outcomes in people with tetraplegic spinal cord injury: perceptual and acoustic measures.Cornwell, PL., Ward, EC., Lim, Y., et al.[2021]
The automated inflatable abdominal binder provides effective venous compression and improves orthostatic tolerance in patients with autonomic failure, showing similar efficacy to the standard treatment, midodrine, in a study of 19 patients.
Combining the binder with midodrine significantly enhances orthostatic tolerance and reduces symptoms more than either treatment alone, indicating a potential for improved management of orthostatic hypotension.
Efficacy of Servo-Controlled Splanchnic Venous Compression in the Treatment of Orthostatic Hypotension: A Randomized Comparison With Midodrine.Okamoto, LE., Diedrich, A., Baudenbacher, FJ., et al.[2018]

References

Control of Pelvic Blood Flow Using a Novel Pneumatic Abdominal Binder. [2021]
Impact of an abdominal binder on speech outcomes in people with tetraplegic spinal cord injury: perceptual and acoustic measures. [2021]
Efficacy of Servo-Controlled Splanchnic Venous Compression in the Treatment of Orthostatic Hypotension: A Randomized Comparison With Midodrine. [2018]
Haemodynamic and respiratory effects of an abdominal compression binder. [2008]
Assessment of Abdominal Constrictor's Forces for Informing Computational Models of Orthostatic Hypotension. [2022]
Elastic Abdominal Binders Attenuate Orthostatic Hypotension in Parkinson's Disease. [2022]